BioCentury
ARTICLE | Clinical News

rectal TOP1288: Phase IIa started

October 17, 2016 7:00 AM UTC

TopiVert began a double-blind, placebo-controlled, European Phase IIa trial to evaluate 200 mg TOP1288 rectal solution once daily for 4 weeks in about 60 patients with moderate to severe disease activ...